Keppra

ApprovedSmall molecule

Teva

Keppra is one of 63 small molecule programs targeting Cervical Dystonia. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical DystoniaActive, not recruiting

SeizureActive, not recruiting

Cervical DystoniaPhase 2

Active, not recruiting

SeizureApproved

Active, not recruiting

Competition

Competitive Landscape

109 competitors in Seizure

#DrugCompanyPhaseTrials

Briviact

UCB

Phase 3

12 2

Afinitor

Novartis

Phase 3

1 3

Fintepla

IImmedica Pharma AB

Phase 3

3 4

E2007

Eisai

Phase 3

6 5

Epsom Salt

FFresenius Kabi Oncology Ltd.

Phase 3

1 6

Ativan

BBausch Health Americas, Inc.

Phase 3

1 7

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

1 8

SPM 929

UCB

Phase 3

3 9

Valproate Sodium

Sanofi

Phase 3

1 10

Carisbamate

SSK Life Science, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Hematologic Disorder

NCT01666080

Clinical

Trials by Indication[1]

Fasting Conditions5 trials

Levetiracetam 1000 mg Under Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT00859521·30 enrolled

Levetiracetam 750 mg Tablets Under Non-Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT00849485·22 enrolled

Levetiracetam 750 mg Tablets Under Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT00849862·22 enrolled

Show 2 more trials

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

Completed· Novartis logo

Novartis·Phase 1·NCT00946751·20 enrolled

Levetiracetam 1000 mg Under Non-Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT00859430·22 enrolled

Cervical Dystonia1 trial

Keppra for Cervical Dystonia

Terminated·UUniversity of South Florida·Phase 2·NCT00760318·17 enrolled

TED1 trial

Bioequivalence Study of Levetiracetam 1500 mg Coated Granules in Healthy, Male Subjects

Completed· Roche logo

Roche·Phase 1·NCT07393022·20 enrolled

Acute Lymphoblastic Leukemia1 trial

Busulfan and Cyclophosphamide Followed By ALLO BMT

Terminated·MMasonic Cancer Center, University of Minnesota·N/A·NCT01685411·5 enrolled

Seizure1 trial

IV Keppra in the Emergency Department for Prevention of Early Recurrent Seizures

Completed·EEmory University·Phase 4·NCT00510783·158 enrolled

2 more indications

Hematologic Disorder1 trial

Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

Recruiting·MMasonic Cancer Center, University of Minnesota·Preclinical·NCT01666080·30 enrolled

Unspecified1 trial

A Bioequivalence Study of Levetiracetam Versus Keppra

Completed·TTri-Service General Hospital·N/A·NCT00926302·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Keppra. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Keppra compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Keppra. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Teva

Keppra

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Fasting Conditions5 trials

Cervical Dystonia1 trial

TED1 trial

Acute Lymphoblastic Leukemia1 trial

Seizure1 trial

Hematologic Disorder1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News